Patents by Inventor Timothy A. Springer
Timothy A. Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580482Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.Type: GrantFiled: February 15, 2013Date of Patent: February 28, 2017Assignee: Children's Medical Center CorporationInventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
-
Publication number: 20160084825Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.Type: ApplicationFiled: November 23, 2015Publication date: March 24, 2016Inventors: Timothy A. Springer, Bing Hao Luo
-
Publication number: 20150147349Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.Type: ApplicationFiled: February 15, 2013Publication date: May 28, 2015Inventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
-
Publication number: 20150044779Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.Type: ApplicationFiled: August 28, 2014Publication date: February 12, 2015Inventors: Timothy A. Springer, Bing Hao Luo
-
Patent number: 8877893Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.Type: GrantFiled: December 23, 2009Date of Patent: November 4, 2014Assignee: Children's Medical Center CorporationInventors: Timothy A. Springer, Bing Hao Luo
-
Publication number: 20130040845Abstract: Embodiments of the invention herein relate to methods of studying binding interactions between two entities and methods for screening of modulators of such binding interactions, in particular, the protein-protein interaction observed in receptor-ligand interactions.Type: ApplicationFiled: February 14, 2011Publication date: February 14, 2013Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Timothy A. Springer, Jongseong Kim
-
Patent number: 8247185Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1 ”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.Type: GrantFiled: March 8, 2011Date of Patent: August 21, 2012Assignees: DYAX Corp., The CBR Institute for Biomedical Research, Inc.Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka
-
Patent number: 8241627Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: June 22, 2011Date of Patent: August 14, 2012Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20110305691Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: June 22, 2011Publication date: December 15, 2011Applicant: THE CENTER FOR BLOOD RESEARCH, INC.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20110212112Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.Type: ApplicationFiled: March 8, 2011Publication date: September 1, 2011Applicant: CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC.Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka
-
Patent number: 7968284Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: December 10, 2010Date of Patent: June 28, 2011Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20110111528Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: December 10, 2010Publication date: May 12, 2011Applicant: THE CENTER FOR BLOOD RESEARCH, INC.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7927591Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.Type: GrantFiled: February 22, 2005Date of Patent: April 19, 2011Assignee: The CBR Institute for Biomedical Research, Inc.Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka
-
Patent number: 7879577Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: November 20, 2009Date of Patent: February 1, 2011Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20100167418Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Timothy A. Springer, Bing Hao Luo
-
Publication number: 20100113742Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: November 20, 2009Publication date: May 6, 2010Applicant: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7674604Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. Modified integrin I-domain polypeptides stabilized in a desired conformation are also provided, as well as screening assays and therapeutic methods utilizing the modified integrin I-domain polypeptides.Type: GrantFiled: March 15, 2005Date of Patent: March 9, 2010Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20090035321Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.Type: ApplicationFiled: December 4, 2006Publication date: February 5, 2009Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
-
Patent number: 7354588Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.Type: GrantFiled: June 7, 1995Date of Patent: April 8, 2008Assignee: Dana Farber Cancer InstituteInventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
-
Publication number: 20080069777Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.Type: ApplicationFiled: February 22, 2005Publication date: March 20, 2008Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka